Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: A multicentre, open, randomised controlled trial

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 3, 2016, Pages 244-253

  Xavier, Denis ^a   Gupta, Rajeev ^b   Kamath, Deepak ^a   Sigamani, Alben ^c   Devereaux, P J ^d   George, Nisha ^a   Joshi, Rajnish ^e   Pogue, Janice ^d   Pais, Prem ^a   Yusuf, Salim ^d  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^b Department of Preventive Cardiology and Internal Medicine   (India)

^c Narayana Health City   (India)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET THERAPY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH AUXILIARY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH PROGRAM; HEALTH PROMOTION; HEART RATE; HOSPITAL DISCHARGE; HUMAN; INDIA; INTENTION TO TREAT ANALYSIS; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; PATIENT EDUCATION; PHYSICAL ACTIVITY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION PROGRAM; TOBACCO USE; TREATMENT OUTCOME; CLINICAL TRIAL; HEALTHY LIFESTYLE; MIDDLE AGED; PSYCHOLOGY; SECONDARY PREVENTION;

ACUTE CORONARY SYNDROME; COMMUNITY HEALTH WORKERS; FEMALE; HEALTHY LIFESTYLE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84959530208     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00480-5     Document Type: Article

References (37)

1. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007, 356:2388-2398.
2. Kahn R, Robertson RM, Smith R, Eddy D The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008, 118:576-585.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
4. Karthikeyan G, Xavier D, Prabhakaran D, Pais P Perspectives on the management of coronary artery disease in India. Heart 2007, 93:1334-1338.
5. Prabhakaran D, Yusuf S, Mehta S, et al. Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2. Indian Heart J 2005, 57:217-225.
6. Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 2014, 371:818-827. the PURE Investigators.
7. Xavier D, Pais P, Devereaux PJ, et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 2008, 371:1435-1442. the CREATE registry investigators.
8. Mohanan PP, Mathew R, Harikrishnan S, et al. Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala acute coronary syndrome Registry. Eur Heart J 2013, 34:121-129. the Kerala acute coronary syndrome Registry Investigators.
9. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011, 378:1231-1243. the Prospective Urban Rural Epidemiology (PURE) Study Investigators.
10. Mendis S, Abegunde D, Yusuf S, et al. WHO study on prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE). Bull World Health Organ 2005, 83:820-829.
11. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapies for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011, 58:2432-2446.
12. Perk J, De Becker G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (Version 2012). The fifth joint task force of the European Society of Cardiology and other societies and by invited experts, developed with special contribution of the European Association for Cardiovascular Prevention and Rehabilitation. Eur Heart J 2012, 33:1635-1701. the European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG).
13. Gupta R, Mony P, Shankar K, et al. Socioeconomic status and cardiovascular secondary prevention therapies in South Asia: the PURE Study. Eur J Prev Cardiol 2015, 22:1261-1271.
14. Teo K, Lear S, Islam S, et al. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. JAMA 2013, 309:1613-1621. the PURE Investigators.
15. Osterberg L, Blaschke T Adherence to medication. N Engl J Med 2005, 353:487-497.
16. Global Health Workforce Alliance. Global experience of community health workers for delivery of health related Millennium Development Goals: a systematic review, country case studies, and recommendations for integration into national health systems 2010, WHO, World Health Organization, Geneva.
17. Beaglehole R, Bonita R, Horton R, et al. Priority actions for the non-communicable disease crisis. Lancet 2011, 377:1438-1447. the Lancet NCD Action Group, the NCD Alliancethe NCD Alliance.
18. Kamath DY, Xavier D, Gupta R, et al. Rationale and design of a randomized controlled trial evaluating community health worker-based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD). Am Heart J 2014, 168:690-697.
19. Morisky DE, Green LW, Levine DM Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67-74.
20. Ades PA Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 2001, 345:892-902.
21. McAlister FA, Lawson FM, Teo KK, Armstrong PW Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ 2001, 323:957-962.
22. Clark AM, Hartling L, Vandermeer B, McAlister FA Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005, 143:659-672.
23. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Pract 2007, 24:189-200. Community Pharmacy Medicines Management Project Evaluation Team.
24. Redfern J, Menzies M, Briffa T, Freedman SB Impact of medical consultation frequency on modifiable risk factors and medications at 12 months after acute coronary syndrome in the CHOICE randomised controlled trial. Int J Cardiol 2010, 145:481-486.
25. Schedlbauer A, Davies P, Fahey T Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010, 3. CD004371.
26. Calvert SB, Kramer JM, Anstrom KJ, Kaltenbach LA, Stafford JA, Allen LaPointe NM Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J 2012, 163:657-665. e1.
27. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012, 157:785-795.
28. Briffa T, Chow CK, Clark AM, Redfern J Improving outcomes after acute coronary syndrome with rehabilitation and secondary prevention. Clin Ther 2013, 35:1076-1081.
29. Brown JP, Clark AM, Dalal H, Welch K, Taylor RS Effect of patient education in the management of coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2013, 20:701-714.
30. Altowaijri A, Phillips CJ, Fitzsimmons D A systematic review of the clinical and economic effectiveness of clinical pharmacist intervention in secondary prevention of cardiovascular disease. J Manag Care Pharm 2013, 19:408-416.
31. Ho PM, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med 2014, 174:186-193.
32. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011, 365:2088-2097. the Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial.
33. Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med 2013, 126:357.e7-357.e27.
34. Jorstad HT, von Birgelen C, Alings AM, et al. Effect of a nurse-coordinated prevention program on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomized trial. Heart 2013, 99:1421-1430.
35. Rosenbaum L, Shrank WH Taking our medicine-improving adherence in the accountability era. N Engl J Med 2013, 369:694-695.
36. Lewin SA, Dick J, Pond P, et al. Lay health workers in primary and community health care. Cochrane Database Syst Rev 2005, 25. CD004015.
37. Topol EJ The creative destruction of medicine: how the digital revolution will create better health care 2012, Basic Books, New York, USA.